The relationship between cardiac troponin in people hospitalised for exacerbation of COPD and major adverse cardiac events (MACE) and COPD readmissions
The relationship between cardiac troponin in people hospitalised for exacerbation of COPD and major adverse cardiac events (MACE) and COPD readmissions
Background: no single biomarker currently risk stratifies chronic obstructive pulmonary disease (COPD) patients at the time of an exacerbation, though previous studies have suggested that patients with elevated troponin at exacerbation have worse outcomes. This study evaluated the relationship between peak cardiac troponin and subsequent major adverse cardiac events (MACE) including all-cause mortality and COPD hospital readmission, among patients admitted with COPD exacerbation.
Methods: data from five cross-regional hospitals in England were analysed using the National Institute of Health Research Health Informatics Collaborative (NIHR-HIC) acute coronary syndrome database (2008–2017). People hospitalised with a COPD exacerbation were included, and peak troponin levels were standardised relative to the 99th percentile (upper limit of normal). We used Cox Proportional Hazard models adjusting for age, sex, laboratory results and clinical risk factors, and implemented logarithmic transformation (base-10 logarithm). The primary outcome was risk of MACE within 90 days from peak troponin measurement. Secondary outcome was risk of COPD readmission within 90 days from peak troponin measurement.
Results: there were 2487 patients included. Of these, 377 (15.2%) patients had a MACE event and 203 (8.2%) were readmitted within 90 days from peak troponin measurement. A total of 1107 (44.5%) patients had an elevated troponin level. Of 1107 patients with elevated troponin at exacerbation, 256 (22.8%) had a MACE event and 101 (9.0%) a COPD readmission within 90 days from peak troponin measurement. Patients with troponin above the upper limit of normal had a higher risk of MACE (adjusted HR 2.20, 95% CI 1.75–2.77) and COPD hospital readmission (adjusted HR 1.37, 95% CI 1.02–1.83) when compared with patients without elevated troponin.
Conclusion: an elevated troponin level at the time of COPD exacerbation may be a useful tool for predicting MACE in COPD patients. The relationship between degree of troponin elevation and risk of future events is complex and requires further investigation.
2405-2416
Kallis, Constantinos
be240681-5de4-4202-8c03-43e0c7526a3e
Kaura, Amit
faf17674-2517-40ac-ad6d-cc67584ebf82
Samuel, Nathan A.
bbd39add-74ac-43fa-8e7a-0f862e8ccee3
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Kallis, Constantinos
be240681-5de4-4202-8c03-43e0c7526a3e
Kaura, Amit
faf17674-2517-40ac-ad6d-cc67584ebf82
Samuel, Nathan A.
bbd39add-74ac-43fa-8e7a-0f862e8ccee3
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Curzen, Nick
,
et al.
(2023)
The relationship between cardiac troponin in people hospitalised for exacerbation of COPD and major adverse cardiac events (MACE) and COPD readmissions.
International Journal of Chronic Obstructive Pulmonary Disease, 18, .
(doi:10.2147/COPD.S432166).
Abstract
Background: no single biomarker currently risk stratifies chronic obstructive pulmonary disease (COPD) patients at the time of an exacerbation, though previous studies have suggested that patients with elevated troponin at exacerbation have worse outcomes. This study evaluated the relationship between peak cardiac troponin and subsequent major adverse cardiac events (MACE) including all-cause mortality and COPD hospital readmission, among patients admitted with COPD exacerbation.
Methods: data from five cross-regional hospitals in England were analysed using the National Institute of Health Research Health Informatics Collaborative (NIHR-HIC) acute coronary syndrome database (2008–2017). People hospitalised with a COPD exacerbation were included, and peak troponin levels were standardised relative to the 99th percentile (upper limit of normal). We used Cox Proportional Hazard models adjusting for age, sex, laboratory results and clinical risk factors, and implemented logarithmic transformation (base-10 logarithm). The primary outcome was risk of MACE within 90 days from peak troponin measurement. Secondary outcome was risk of COPD readmission within 90 days from peak troponin measurement.
Results: there were 2487 patients included. Of these, 377 (15.2%) patients had a MACE event and 203 (8.2%) were readmitted within 90 days from peak troponin measurement. A total of 1107 (44.5%) patients had an elevated troponin level. Of 1107 patients with elevated troponin at exacerbation, 256 (22.8%) had a MACE event and 101 (9.0%) a COPD readmission within 90 days from peak troponin measurement. Patients with troponin above the upper limit of normal had a higher risk of MACE (adjusted HR 2.20, 95% CI 1.75–2.77) and COPD hospital readmission (adjusted HR 1.37, 95% CI 1.02–1.83) when compared with patients without elevated troponin.
Conclusion: an elevated troponin level at the time of COPD exacerbation may be a useful tool for predicting MACE in COPD patients. The relationship between degree of troponin elevation and risk of future events is complex and requires further investigation.
Text
The Relationship Between Cardiac Troponin in People Hospitalised for Exacerbation of COPD and Major Adverse Cardiac Events MACE and COPD Readmission
- Version of Record
More information
Accepted/In Press date: 1 November 2023
e-pub ahead of print date: 5 November 2023
Identifiers
Local EPrints ID: 492026
URI: http://eprints.soton.ac.uk/id/eprint/492026
PURE UUID: 6c63a70d-d663-4500-b5cb-a2fcdc04fc57
Catalogue record
Date deposited: 11 Jul 2024 17:12
Last modified: 12 Nov 2024 02:41
Export record
Altmetrics
Contributors
Author:
Constantinos Kallis
Author:
Amit Kaura
Author:
Nathan A. Samuel
Corporate Author: et al.
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics